U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06879340) titled 'Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients with Relapsed or Refractory B-cell Malignancies' on March 03.
Brief Summary: This multicenter phase 1 trial with "3 + 3" dose escalation design seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of chimeric antigen receptors targeting the B cell surface antigens CD19/20/22 following administration of a chemotherapy lymphodepletion regimen in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) or Non-Hodgkin's lymphoma (NHL). The overall goals of this s...